Relevant clinical end points in biphosphonate trials
- PMID: 9738595
- DOI: 10.1200/JCO.1998.16.9.3204
Relevant clinical end points in biphosphonate trials
Comment on
-
Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review.J Clin Oncol. 1998 Mar;16(3):1218-25. doi: 10.1200/JCO.1998.16.3.1218. J Clin Oncol. 1998. PMID: 9508210 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
